Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Executive summary

Budget impact of AD109

3 evidence topics · 15 sources

Summary: price and budget impact model status

AD109 is under FDA review: the NDA was submitted in April 2026 and accepted in July 2026, with a PDUFA goal date of February 28, 2027. No price for AD109 has been published, and no budget impact model or product-specific economic evaluation was identified.

Summary: company statements on the addressable population
  • Total addressable population: the prospectus cites approximately 80 million U.S. adults aged 30 to 69, from a study Apnimed commissioned from Clarivate, and approximately one billion people worldwide, attributed to the World Health Organization. The published Clarivate and Apnimed estimate, authored by employees of both companies, reports 83.7 million U.S. adults aged 20 years and older with AHI4 of 5 or more in 2024 (52% mild, 30% moderate, 18% severe).
  • Diagnosed populations: approximately three million people newly diagnosed each year (Komodo medical claims database), approximately 23 million unique patients with a diagnosis of OSA active in the health care system from 2019 to 2024 (Apnimed analysis of IQVIA claims), and approximately 10.5 million people diagnosed but not receiving treatment (National Sleep Foundation).
  • The 10.5 million figure comes from a 2025 National Sleep Foundation survey, conducted with support from Inspire Medical Systems, of 1,015 U.S. adults aged 18 to 90 who reported their own diagnosis and treatment status; it states that approximately 31%, or over 10.5 million adults, diagnosed with sleep apnea are not receiving treatment.
  • Initial launch population: Apnimed intends to focus its initial launch on the approximately 10.5 million diagnosed but untreated people; a 2026 company presentation lists, beside that initial target, diagnosis within the past 2 years and intolerance to PAP (refused or failed).
  • Company market research among payers reports that payers perceive PAP non-compliance at greater than 60%.
Summary: published cost evidence for obstructive sleep apnea and its treatments
  • Cost of illness: a Frost & Sullivan report estimated that undiagnosed OSA cost the United States approximately $149.6 billion in 2015, and its financial modeling put treatment costs at approximately 33% of non-treatment costs. Among U.S. Medicare beneficiaries, those with OSA (n = 10,317) had mean total annual costs $19,566 (95% CI $13,239 to $25,894) higher than matched controls in the year before diagnosis.
  • CPAP cost-effectiveness: in a lifetime Markov model, CPAP for moderate to severe OSA had an incremental cost-effectiveness ratio of $15,915 per QALY gained. A second analysis reported $3354 per QALY from a third-party payer perspective and $314 per QALY from a societal perspective. A third analysis reported $12 495 per DALY averted from the health care system perspective, with CPAP dominant from a societal perspective. A meta-analysis of 15 studies reported an incremental net benefit of $13,024 (95% CI $6,813 to $19,236) for CPAP against other treatments, with low certainty.
  • Hypoglossal nerve stimulation: a 5-state Markov model estimated a lifetime incremental cost of $42,953 and an incremental cost-effectiveness ratio of $39,471 per QALY.
  • Coverage of current treatments: Medicare covers CPAP initially for a 12-week period and continues coverage only for beneficiaries who benefit during that period. CMS states that beneficiaries prescribed Zepbound for moderate to severe OSA in adults with obesity should continue to receive Medicare Part D coverage, subject to the plan's utilization management requirements, and a commercial prior authorization policy grants tirzepatide for OSA for an initial 6 months and continuation for 12 months.